A total of 363 patients were excluded from the analysis: diagnosis of diabetes types other than Type 2 diabetes (n = 88), GAD antibody–positive (n = 45), diagnosis of an endocrine disorder (n = 8), diagnosis of liver cirrhosis (n = 6), history of pancreatic surgery (n = 2), use of corticosteroids (n = 1), diagnosis of sleep apnea syndrome (n = 19), professional CGM wearing period < 7 days (n = 44), initiation of professional CGM during hospitalization (n = 139), and use of multiple hypnotics (n = 11). This evidence concerns the gene GAD1 and cirrhosis of liver.